BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Farmers Insurance

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,722,037

« Back to Dashboard

Which drugs does patent 8,722,037 protect, and when does it expire?

Patent 8,722,037 protects NEXPLANON and is included in one NDA.

This patent has thirty-two patent family members in thirty-one countries.

Summary for Patent: 8,722,037

Title:X-ray visible drug delivery device
Abstract: The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.
Inventor(s): Veenstra; Harm (Oss, NL), De Graaff; Wouter (Oss, NL)
Assignee: Meck Sharp & Dohme B.V. (BN Harleem, NL)
Application Number:10/592,725
Patent Claim Types:
see list of patent claims
Compound; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Organon Usa IncNEXPLANONetonogestrelIMPLANT;IMPLANTATION021529-002May 31, 2011RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,722,037

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04101151Mar 19, 2004
PCT Information
PCT FiledMarch 14, 2005PCT Application Number:PCT/EP2005/051150
PCT Publication Date:September 29, 2005PCT Publication Number: WO2005/089814

International Patent Family for Patent: 8,722,037

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2559250► Subscribe
China1953770► Subscribe
Cyprus1108362► Subscribe
Germany602005007873► Subscribe
Denmark1729819► Subscribe
EcuadorSP066865► Subscribe
Egypt24359► Subscribe
European Patent Office1729819► Subscribe
Spain2308460► Subscribe
Hong Kong1096316► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Fish and Richardson
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: